Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female infants, 8 to 16 weeks of age at the time of the first vaccination.~Exclusion Criteria:~* Previous vaccination against OR history of OR exposure since birth to diphtheria, pertussis, tetanus, polio, hepatitis B, Hib and/or meningococcal disease.~* Planned administration/administration of a vaccine not foreseen in the study since birth.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* A family history of congenital or hereditary immunodeficiency.~* History of any neurologic disorders or seizures, allergic disease or reactions likely to be exacerbated by any component of the vaccine

- Gender: ALL
- Minimum Age: 8 Weeks
- Maximum Age: 16 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).